Evidence map›Paper›PMID 40455230›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2025

Unraveling the therapeutic landscape of miRNAs in pancreatic cancer.

Zeinab A El-Moaty, Maria Wagdy Wasef, Yara A Elsayed, Amina Sayed Shafiq, Mai A Elnagar, Hadeer Rashad Mohamed, Ahmed E Elesawyf, Sherif S Abdel Mageedg, Osama A Mohammed, Mustafa Ahmed Abdel-Reheim and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zeinab A El-MoatyBiological Sciences Department, College of Science, King Faisal University, Al-Ahsa, 31982, Saudi Arabia. zeahmed@kfu.edu.sa.ORCID http://orcid.org/0000-0002-9011-8234
Maria Wagdy WasefDepartment of Biochemistry, Faculty of Science, Cairo University, Cairo, 12613, Egypt.
Yara A ElsayedBiotechnology Department, Faculty of Science, Ain Shams University, Cairo, 11566, Egypt.
Amina Sayed ShafiqDepartment of Biochemistry, Faculty of Science, Cairo University, Cairo, 12613, Egypt.
Mai A ElnagarZewail City of Science and Technology, October Gardens, 6 th of October City, Giza, Egypt.
Hadeer Rashad MohamedBiochemistry and Nutrition Department, Faculty of Women For Arts, Science & Education, Ain-Shams University, Cairo, 11757, Egypt.
Ahmed E ElesawyfDepartment of Biochemistry, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, 11829, Egypt.
Sherif S Abdel MageedgPharmacology and Toxicology Department, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, 11829, Egypt.
Osama A MohammedDepartment of Pharmacology, College of Medicine, University of Bisha, Bisha, 61922, Saudi Arabia.
Mustafa Ahmed Abdel-ReheimDepartment of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Shaqra, 11961, Saudi Arabia. m.ahmed@su.edu.sa.ORCID http://orcid.org/0000-0002-7728-0923
Rabab S HamadBiological Sciences Department, College of Science, King Faisal University, Al-Ahsa, 31982, Saudi Arabia.
Raydaa Abdullah S AlshomraniCollege of Medicine, University of Bisha, Bisha, 61922, Saudi Arabia.
Ahmed S DoghishDepartment of Biochemistry, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, 11829, Egypt. ahmed_doghish@azhar.edu.eg.ORCID http://orcid.org/0000-0002-0136-7096

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), remains one of the deadliest malignancies with a dismal prognosis due to late diagnosis and limited effective treatments. This review explores the multifaceted role of circulating and exosomal microRNAs (miRNAs) in pancreatic cancer progression, metastasis, diagnosis, prognosis, and therapeutic potential. miRNAs-a class of small non-coding RNAs-regulate gene expression post-transcriptionally, influencing key oncogenic and tumor-suppressor pathways. Dysregulated miRNA expression correlates with tumor stages, metastasis, and patient survival, presenting promising biomarkers for early detection and monitoring disease progression. Oncogenic miRNAs like miR-21 and miR-10b are elevated in the serum exosomes of PDAC patients and contribute to tumor growth and therapy resistance by modulating pathways such as Ras/ERK and promoting epithelial-mesenchymal transition. Advances in combining miRNA profiles with traditional markers have significantly improved diagnostic accuracy, highlighting miRNAs as robust tools for early intervention. Furthermore, targeting miRNAs therapeutically, either through anti-miRNA oligonucleotides or modulation of their regulatory networks, offers novel approaches to overcome chemoresistance and impede tumor progression. This review synthesizes current understanding and emerging insights into miRNA-driven molecular mechanisms in pancreatic cancer, underscoring their critical role in shaping future diagnostic and therapeutic landscapes.

Indexed as

Carcinoma, Pancreatic DuctalMicroRNAsPancreatic NeoplasmsAnimalsBiomarkers, TumorGene Expression Regulation, NeoplasticHumansBiomarkers, TumorMicroRNAsBiomarkersDiagnosisMiRNAPancreatic cancerPancreatic ductal adenocarcinoma (PDAC)Prognosis

Identifiers

PMID40455230

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.